← Back to Clinical Trials
Recruiting NCT06017817

NCT06017817 Antibacterial Photodynamic Therapy in the Management of Peri-implantitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06017817
Status Recruiting
Phase
Sponsor Nilminie Rathnayake
Condition Peri-Implantitis
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-05-13
Primary Completion 2025-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Lumoral TreatmentStandard oral hygiene instructionsScaling and root planing (SRP

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-05-13 with a primary completion date of 2025-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This early-stage study is designed to determine the efficacy of the Lumoral method in periimplantitis. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. In addition, the device might have a photobiomodulation effect on periodontal tissues, thus impacting osseointegration.

Eligibility Criteria

Inclusion Criteria: * PPD ≥6 mm and marginal bone loss \>3 mm * Dental implants collected and clinically characterized according to Lähteenmäki et al. CEDR-22 * Agreement to participate in the study and to sign a written consent form * Able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol Exclusion Criteria: * Presence of any physical limitation or restriction that might restrict Lumoral use * Unwilling to participate in the study * Pregnancy or lactation * Active smoking * Medicated diabetes mellitus (DM) * Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of peri-implantitis * Use of antibiotics and doxycycline, chlorhexidine, and bisphosphonates, within 4 weeks week prior to study participation * Peri-implant and periodontal treatment within 3 months prior to study participation * Removable major prosthesis or major orthodontic appliance

Contact & Investigator

Central Contact

Mikko Kylmänen

✉ mikko.kylmanen@koitehealth.com

📞 +358407245934

Principal Investigator

Nilminie Rathnayake, Assoc Prof

PRINCIPAL INVESTIGATOR

University of Helsinki

Frequently Asked Questions

Who can join the NCT06017817 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Peri-Implantitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06017817 currently recruiting?

Yes, NCT06017817 is actively recruiting participants. Contact the research team at mikko.kylmanen@koitehealth.com for enrollment information.

Where is the NCT06017817 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT06017817 clinical trial?

NCT06017817 is sponsored by Nilminie Rathnayake. The principal investigator is Nilminie Rathnayake, Assoc Prof at University of Helsinki. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology